This year has started out at high pace with great progress in UAE, further internal growth and continued market preparations. Arab Health 2019 (https://www.arabhealthonline.com/en/Home.html) in Dubai was a very fruitful event and the perfect opportunity to introduce Actiste to the global industry leaders and to deepen our relationships with local stakeholders, as well as initiating new relationships in the broader GCC region. Above all, we got some very encouraging words from UAE Ministry of Health and Prevention on launching our diabetes service Actiste in UAE.
Intensive work is now underway to utilize the momentum that has been built up, expand the organization further and commercialize Actiste in UAE and the broader GCC region, Sweden, Thailand and Indonesia. Once the ongoing CE certification of Actiste is completed the market introduction can move on to its next phase: actual real-life use.
February 22 - 8 March 2019 is exercise period of Brighter Warrants TO4 during which holders of Warrants can subscribe for shares. One (1) TO4 can be exchanged for one (1) share during the period, at a price of SEK 6.01.
In total Brighter would receive approximately SEK 77 million if all Warrants of series TO4 were to be exercised, minimizing Brighter's need for external financing and accelerating future growth.
Truls Sjöstedt, CEO & founder
Holders of warrants who have their Warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the Warrants and subscribe for the corresponding shares.
Exercise of the Warrants and subscription of shares for other holders of Warrants takes place through simultaneous payment and submittal of the registered application form, signed and submitted to the Company's share agent (Eminova Fondkommission) no later than 16:00 CET on March 8th, 2019.
As part of Brighter's historical financing strategy and the agreement with L1 Capital (finalized and terminated January 2019), the company has distributed free warrants (TO3 and TO4) to its shareholders to reduce dilution.
For terms and conditions of the Warrants, please visit: https://brighter.se/investors/financing
In case of need of further assistance or questions, please contact the company's share agent Eminova Fondkommission by phone (08-684 211 00) or by email (firstname.lastname@example.org).
For further information, please contact:
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.
Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. https://actiste.com/
About Brighter AB (publ)
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. https://brighter.se/
The Company's shares are listed on NASDAQOMX First North/BRIG (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE86375). Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 - 684 211 00, email@example.com, www.eminova.se.
This information was distributed by Cision http://www.cisionwire.se/